The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Triggering global regulatory submissions this year for the treatment of obesity
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Subscribe To Our Newsletter & Stay Updated
